Translations:Angiotensin II receptor blocker/33/en

|- | Valsartan | Diovan | 6 | 2–4 hrs | 95% | 25% | 30/70% | Yes | 80–320 | Substrates: MRP2 and OATP1B1/SLCO1B1 |- | Irbesartan | Avapro | 11–15 | 1.5–2 hrs | 90–95% | 70% | 20/80% | No | 150–300 | Minor substrates of CYP2C9 |- | Telmisartan | Micardis | 24 | 0.5–1 hr | >99% | 42–58% | 1/99% | No | 40–80 | None known; >97% via biliary excretion |- | Eprosartan | Teveten | 5 | 1–2 hrs | 98% | 13% | 30/70% | No | 400–800 | None known; >90% via renal and biliary excretion |- | Olmesartan | Benicar/Olmetec | 14–16 | 1–2 hrs | >99% | 29% | 40/60% | No | 10–40 | Substrates of OATP1B1/SLCO1B1 |- | Azilsartan | Edarbi | 11 | 1.5–3 hrs | >99% | 60% | 55/42% | No | 40–80 | Minor substrates of CYP2C9 |- | Fimasartan | Kanarb | 7–11 | 0.5–3 hrs after dosing. | >97% | 30–40% | – | – | 30–120 | None known; primarily biliary excretion |- ! Drug ! Trade name ! Biological half-life [hrs] ! Peak plasma concentration [Tmax] ! Protein binding [%] ! Bioavailability [%] ! Renal/hepatic clearance [%] ! Food effect ! Daily dosage [mg] ! Metabolism/transporter |}